Immune checkpoint inhibitors: Navigating a new paradigm of treatment toxicities.
about
Current and future immunotherapies for thyroid cancer.HLA-associated drug hypersensitivity and the prediction of adverse drug reactions.Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi.Clinical Safety of Combined Targeted and L. Therapy in Oncological Patients
P2860
Immune checkpoint inhibitors: Navigating a new paradigm of treatment toxicities.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
Immune checkpoint inhibitors: Navigating a new paradigm of treatment toxicities.
@en
Immune checkpoint inhibitors: Navigating a new paradigm of treatment toxicities.
@nl
type
label
Immune checkpoint inhibitors: Navigating a new paradigm of treatment toxicities.
@en
Immune checkpoint inhibitors: Navigating a new paradigm of treatment toxicities.
@nl
prefLabel
Immune checkpoint inhibitors: Navigating a new paradigm of treatment toxicities.
@en
Immune checkpoint inhibitors: Navigating a new paradigm of treatment toxicities.
@nl
P2093
P2860
P356
P1476
Immune checkpoint inhibitors: Navigating a new paradigm of treatment toxicities.
@en
P2093
Kenneth O'Byrne
Vanessa Culleton
Zarnie Lwin
P2860
P304
P356
10.1111/AJCO.12698
P577
2017-07-12T00:00:00Z